v3.26.1
Consolidated Statements of Cash Flows - CAD ($)
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Jan. 31, 2024
Operating activities      
Net loss $ (1,512,918) $ (3,621,884) $ (2,898,510)
Adjustments to reconcile net loss to net cash used in operating activities:      
Accretion expense (Notes 5 and 6) 77,547 154,387 5,353
Changes in fair values of warrant liabilities (Notes 9(a) and 9(b)) (197,923) 33,436 137,764
Financial guarantee liability (Note 16(c)) 30,426 (758,834) 34,050
Foreign exchange loss (200,861) 275,182 26,190
Gain on extinguishment/forgiveness of debts (Note 14) (149,993) (110,219) (469,129)
Gain on extinguishment of loan (9,949) 0 0
Interest expense (44,215) 65,465 0
Penalties recovery 0 (305,437) 0
Settlements and legal provisions, net (Note 16(a)) 0 (556,640) (130,000)
Share-based payments (Notes 11(b), 11(c), 11(d) and 14) 169,752 2,049,925 500,263
Changes in working capital accounts:      
Amounts receivable 8,800 27,911 (22,350)
Prepaids and other current assets 661 42,688 (198,603)
Accounts payable and accrued liabilities 241,907 108,830 (701,563)
Due to related parties 961,311 573,438 1,244,125
Net cash used in operating activities (625,455) (2,021,752) (2,472,410)
Financing activities      
Proceeds from convertible debenture, net (Note 5) 0 1,224,200 300,000
Proceeds from exercise of warrants 25,000 0 0
Proceeds from issuance of common shares and warrants, net (Note 8) 0 705,000 2,201,543
Proceeds from promissory notes (Note 7) 411,000 0 0
Proceeds from subscriptions received (Notes 8(d), 8(j) and 14) 198,191 43,100 0
Proceeds from subscriptions received by MedMelior (Note 11) 0 20,240 0
Repayment of loans payable (Note 6) (4,928) 0 0
Net cash provided by financing activities 629,263 1,992,540 2,501,543
Effects of exchange rate changes on cash 582 8 (56)
Net change in cash 4,390 (29,204) 29,077
Cash - beginning of year 8,180 37,384 8,307
Cash - end of year $ 12,570 $ 8,180 $ 37,384